Robbins LLP Alert for EyePoint Investors In Class Action Lawsuit Regarding Drug Viability
EyePoint Investors Be Aware of Class Action Lawsuit
Investors who hold shares of EyePoint, Inc. (NASDAQ: EYPT) should be cautious as a class action lawsuit has been filed against the company. The law firm Robbins LLP announced that they are representing investors who purchased securities between May 27, 2025, and August 14, 2026. This period is crucial as significant allegations about misleading claims regarding EyePoint's drug efficacy have surfaced.
Allegations Against EyePoint
EyePoint, a company that focuses on developing therapeutics for serious retinal diseases, stands accused of providing misleading information concerning the effectiveness and commercial viability of DURAVYU, a treatment aimed at wet age-related macular degeneration (wet AMD).
During the class period, much of the misleading information revolved around the supposed uniqueness of DURAVYU's mechanism of action and its touted best-in-class efficacy. The core issue is that, according to the plaintiffs, EyePoint inflated the drug's potential effectiveness without disclosing critical information that reflected its actual clinical performance.
Impact on Stock Value
The negative impact of these revelations on EyePoint’s stock has been significant. On August 17, 2026, the company's stock price dropped by an alarming 66.98%, after a press release detailed that DURAVYU did not meet its primary endpoint in clinical trials. This decline continued with another drop of 85.28% on October 19, 2026, following the release of disappointing trial results from the LUCIA study and an announcement regarding workforce reduction.
Investors are encouraged to get in touch with Robbins LLP for a discussion about their options, including serving as a lead plaintiff in the case. Serving as a lead plaintiff allows an investor to represent the collective interests of all class members throughout this litigation. However, it’s important to note that even if you do not wish to assume this role, you can still recover any losses if the case is successful.
No Upfront Costs to Participate
Robbins LLP represents investors on a contingency fee basis, meaning there are no upfront fees or expenses for participating in this lawsuit. This can provide peace of mind for many affected investors who may be apprehensive about potential legal costs.
To learn more about the specific details of the lawsuit or to receive further updates on EyePoint, contact Robbins LLP directly. If you or someone you know has experienced significant losses by investing in EyePoint during the class period, it is crucial to get the proper legal advice and support.
Why Robbins LLP?
Established as a leader in shareholder rights litigation, Robbins LLP has a proven track record of success in similar cases. The firm has reclaimed billions for shareholders and continues to strive for transparency and fairness in the financial markets. Their commitment is to ensure that companies disclose complete and accurate information to prevent such misleading situations in the future.
Investors are empowered to take action during this critical time, and gaining knowledge through Robbins LLP can greatly aid their recovery processes. Be vigilant and informed about your investments, and don’t hesitate to reach out for legal assistance if your rights as a shareholder have been compromised.